Viking Therapeutics, Inc.
VKTX
Positions held
Your positionsVKTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Viking Therapeutics operates in the biotechnology sector, which is known for its potential high returns due to innovative therapies and treatments.
- The company has a strong recommendation of 'strong buy' from analysts, indicating positive investor sentiment.
- Viking Therapeutics has a current ratio of 4.72, suggesting it has sufficient short-term assets to cover its liabilities.
- Viking Therapeutics has reported no revenue for multiple quarters, indicating challenges in monetizing its products.
- The company has a negative profit margin of 0.0%, reflecting ongoing financial losses.
- Viking's net income for the year 2025 is projected to be -359.639 million, highlighting significant financial struggles.
Fundamentals
| Market cap | $3.53B | Enterprise value | $2.74B | Trailing P/E | — | Forward P/E | -6.30 |
| PEG | — | Price / book | 7.92 | Beta | 0.65 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -88.9% | ROA | -51.9% | Debt / equity | 0.01 |
| Current ratio | 4.72 | Free cash flow | -$230.79M | Analyst recommendation | strong_buy | Mean target | $94.71 |
| 52w high | $43.15 | 52w low | $25.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$128M | -$158M | -$158M | -$90.8M | -$65.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$133M | -$164M | -$165M | -$98.6M | -$74.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$360M | -$110M | -$85.9M | -$68.9M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$393M | -$151M | -$101M | -$70.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
2026-10-08 · Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months
2026-10-08 · LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
2026-10-07 · VKTX Advances Obesity Program With New Oral Maintenance Study
2026-10-06 · INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
2026-10-06 · VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
2026-10-06 · Viking Therapeutics Initiates Trial of VK2735 Maintenance Dosing Regimens in Obesity
2026-10-06 · Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
2026-10-05 · Here Are My Top 4 Stocks to Buy in October
2026-10-02 · Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?
2026-10-02 · Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
2026-10-02 · LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Price (daily)
Full chart · RSI · MACD · patterns